Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy Filing
February 27, 2023 08:00 ET
|
Lucira Health Inc.
Lab-quality results for both COVID-19 and Flu now available at home from one single testCOVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access...
($20.47 Billion), eClinical Solutions Market Growth Forecasts at 13.6% CAGR, Globally, by 2028 – Comprehensive Report by The Insight Partners
February 27, 2023 07:33 ET
|
The Insight Partners
New York, Feb. 27, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “eClinical Solutions Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global...
Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19
February 23, 2023 09:00 ET
|
InSilico Medicine
New York, Feb. 23, 2023 (GLOBE NEWSWIRE) -- ISM3312 is a highly selective 3CLpro inhibitor with a novel molecular structure optimized from compounds designed by Chemistry42, Insilico’s...
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
February 22, 2023 08:30 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UK’s National Institute for Health and Care Excellence (NICE) provided positive final...
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
February 21, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling in Germany/Switzerland Basel, Switzerland, 20 February 2023. Kinarus Therapeutics...
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
February 17, 2023 08:55 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial
February 15, 2023 09:00 ET
|
GeoVax, Inc.
Mobile Community Clinical Research Facility to be Deployed in California ATLANTA, GA, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
American Institutes for Research to Lead Federal Research Network on Pandemic Learning Loss and Recovery
February 14, 2023 12:00 ET
|
American Institutes for Research
Arlington, Va., Feb. 14, 2023 (GLOBE NEWSWIRE) -- The American Institutes for Research (AIR) is leading a federally funded network that will conduct and share research that addresses learning...
New to The Street Announces its Line-up, Four Interviews on Episode #438, Airing on the Fox Business Network, Tonight, Monday, February 13, 2023, 10:30 PM PT
February 13, 2023 09:30 ET
|
FMW Media Works Corp
NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) -- FMW Media’s New to The Street announces the broadcastings of its nationally syndicated shows on the Fox Business Network tonight, Monday, February 13,...
Veru Reports Fiscal 2023 First Quarter Financial Results
February 09, 2023 06:30 ET
|
Veru Inc.
Sabizabulin for moderate to severe COVID-19 under review for potential emergency authorization by multiple global regulatory agencies Presented late-breaker oral presentation at IDWeek; sabizabulin...